Striatonigral degeneration

Summary

Striatonigral degeneration (MONDO:0003122) is a disease. A subtype of multiple system atrophy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	striatonigral degeneration
Mondo ID	MONDO:0003122
MeSH	D020955
OMIM	271930
DOID	DOID:4751
ICD-10-CM	G23.2
ICD-11	195535779
NCIT	C125695
SNOMED CT	29618004
UMLS	C0270733
MedGen	124366
GARD	0023374
Is cancer (heuristic)	no

Data availability: 2 cell lines.

Disease family

This is a subtype of multiple system atrophy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › neurodegenerative disease › synucleinopathy › multiple system atrophy › striatonigral degeneration

Related subtypes (3): multiple system atrophy, cerebellar type, pure autonomic failure, multiple system atrophy, parkinsonian type

Subtypes (3): striatal degeneration, autosomal dominant, familial infantile bilateral striatal necrosis, striatonigral degeneration, childhood-onset

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.